The transition from early-stage biologics research to IND-enabling development represents one of the most critical phases in modern biopharmaceutical programs. At this stage, promising therapeutic candidates must evolve from laboratory-scale concepts into robust, scalable, and analytically supported manufacturing processes capable of meeting increasingly stringent quality and regulatory expectations.
Many biologics that perform well during discovery or preclinical research encounter substantial challenges during this transition. Issues such as inconsistent product quality, poor scalability, inadequate process characterization, insufficient analytical readiness, and unstable formulations can significantly delay development timelines and increase manufacturing risks.
Profacgen provides integrated IND-Enabling CMC Development Services designed to help biotechnology companies, pharmaceutical developers, and research organizations establish manufacturing-ready development strategies before entering formal GMP production. Our services combine process characterization, upstream and downstream optimization, analytical method development, formulation studies, impurity control, and technology transfer preparation into a coordinated CMC-focused workflow.
Rather than treating process development as a collection of isolated technical activities, Profacgen emphasizes a phase-appropriate development strategy centered on scalability, process robustness, product consistency, and regulatory readiness.
Our multidisciplinary teams support a broad range of biologics programs, including monoclonal antibodies, bispecific antibodies, fusion proteins, recombinant proteins, ADCs, enzymes, cytokines, vaccine antigens, and complex glycoproteins.
A biologic candidate may demonstrate strong biological activity during early research while still remaining unsuitable for IND submission or clinical manufacturing. Common development risks include:
Without sufficient CMC preparation, these issues often emerge during later development stages, where corrective actions become significantly more expensive and time-consuming.
IND-enabling development serves as the bridge between exploratory research and manufacturing execution. Its primary objective is to establish a scientifically controlled and scalable process framework capable of supporting regulatory progression and future GMP manufacturing activities.
At Profacgen, our IND-enabling strategy focuses on:
By integrating these activities early, we help clients reduce downstream development risks and accelerate the transition toward clinical manufacturing readiness.
Profacgen provides comprehensive support across multiple aspects of CMC-focused biologics development.
Successful IND-enabling development begins with a thorough understanding of the target molecule, manufacturing strategy, and intended clinical pathway.
Our scientists evaluate:
Based on these evaluations, we establish a customized development plan aligned with your molecule's unique characteristics and project timeline.
Robust upstream processing is essential for achieving reproducible product quality and scalable manufacturing performance.
Cell Culture Process Development
Profacgen supports multiple biologics expression systems, including:
Our upstream development services include:
Rather than focusing solely on maximizing titer, our IND-enabling strategy prioritizes balanced optimization between productivity, product quality, process stability, and scalability.
Process Characterization Studies
A critical component of IND-enabling development involves understanding how process parameters influence product quality.
Profacgen performs process characterization studies to evaluate:
These studies help establish a stronger process understanding framework that supports future validation and manufacturing activities.
Efficient downstream purification is essential for impurity control, product consistency, and manufacturing scalability.
Purification Strategy Development
Our downstream development teams design purification workflows optimized for:
We support multiple purification technologies, including:
Impurity Control Strategy Development
IND-enabling development requires systematic control of both process-related and product-related impurities.
Profacgen provides impurity assessment and removal strategies for:
Our teams integrate impurity monitoring throughout process optimization activities to support long-term manufacturing consistency.
Virus Clearance & Safety Evaluation
For biologics requiring advanced safety assessment, we support:
These activities contribute to manufacturing readiness and risk mitigation prior to clinical production.
Analytical readiness is a cornerstone of successful IND-enabling development. Inadequate analytical methods often become major bottlenecks during later regulatory stages.
Profacgen provides integrated analytical development services designed to support process understanding, comparability assessment, and product quality evaluation.
Physicochemical Characterization
We provide comprehensive characterization support for [Monoclonal Antibodies] [Bispecific Antibodies] [Fusion Proteins] [Recombinant Proteins] [ADCs] [Complex Glycoproteins].
Our characterization capabilities include:
These studies help establish product consistency during process optimization and scale-up.
Bioactivity & Functional Assays
We develop and optimize functional assays for:
Functional characterization helps support comparability assessments and process consistency evaluation.
ADC Characterization Support
For antibody-drug conjugate (ADC) programs, we provide:
Analytical Method Development & Qualification
Our analytical development services include:
Strong analytical readiness enables smoother transitions into IND-enabling manufacturing and future GMP activities.
Formulation strategy significantly influences product stability, manufacturability, storage compatibility, and long-term development success.
Profacgen provides formulation development services designed to support IND-ready product profiles.
Formulation Screening & Optimization
We evaluate formulation parameters including:
Our formulation development approach aims to improve:
We conduct multiple stability assessments, including:
These studies support formulation optimization and product handling strategy development.
Lyophilization Process Development
For biologics requiring freeze-dried formulations, we support:
As development progresses toward clinical manufacturing, comparability and process consistency become increasingly important.
Profacgen supports:
Our goal is to establish a development framework capable of supporting future manufacturing continuity and regulatory progression.
One of the most common causes of manufacturing delays involves incomplete or poorly organized technology transfer packages.
Profacgen helps clients prepare for successful transfer into pilot-scale or GMP manufacturing environments through:
These activities help reduce operational risk during manufacturing transition.
Challenge:
A biotechnology company developing a bispecific antibody encountered substantial batch variability during scale-up studies prior to IND-enabling development. Product heterogeneity and aggregation levels increased significantly under modified upstream conditions, creating concerns regarding process robustness and comparability across manufacturing runs. The client needed a comprehensive strategy to identify critical process parameters, reduce aggregation, and improve batch-to-batch consistency.
Solution:
Profacgen performed a systematic process optimization and analytical comparability workflow. Upstream parameter screening identified critical cell culture variables influencing product heterogeneity. Process characterization studies established acceptable operating ranges for temperature, pH, and feeding schedules. Aggregate monitoring using SEC-HPLC quantified high molecular weight species across batches. Chromatography optimization improved purification reproducibility. Analytical comparability assessment demonstrated consistency between optimized batches.
Outcome:
The optimized workflow achieved improved process consistency with significantly reduced aggregation levels. Enhanced purification reproducibility delivered better batch comparability and increased manufacturing readiness. The client successfully advanced the program into IND-enabling manufacturing activities with a robust, well-characterized process capable of producing consistent bispecific antibody material meeting quality targets.
Challenge:
A recombinant fusion protein exhibited substantial instability during freeze-thaw cycles and accelerated storage studies, limiting its suitability for long-term development. The protein showed increasing aggregation after each freeze-thaw event, with visible particle formation within two cycles. Accelerated storage studies revealed rapid loss of native structure and declining biological activity over time, raising concerns about manufacturability and shelf-life potential.
Solution:
Profacgen developed a comprehensive formulation development workflow. Buffer screening evaluated multiple pH conditions and ionic strengths for optimal stability. Excipient compatibility studies tested sugars, polyols, and surfactants for protective effects against aggregation. Freeze-thaw stability assessments quantified activity retention after repeated cycles. Aggregation monitoring using SEC-HPLC tracked high molecular weight species. Accelerated degradation studies predicted long-term stability behavior.
Outcome:
The optimized formulation demonstrated improved storage stability with reduced aggregation levels. Better freeze-thaw tolerance enabled multiple cycles without significant activity loss. The formulation enhanced robustness against thermal stress. The resulting formulation successfully supported continued preclinical development, providing a stable, manufacturable product suitable for further advancement toward clinical studies.
Fill out this form and one of our experts will respond to you within one business day.